Specifically, EGFR-TKIs which were combined with monoclonal antibodies targeting the MET receptor tyrosine kinase, have been studied in patients with advanced NSCLC with deregulated MET, predominantly due to exon 14 skipping mutations or MET gene amplification. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.